nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—CYP3A4—prostate cancer	0.149	1	CbGaD
Lisuride—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0561	0.154	CbGbCtD
Lisuride—CYP2D6—Bicalutamide—prostate cancer	0.0464	0.128	CbGbCtD
Lisuride—CYP2D6—Abiraterone—prostate cancer	0.0384	0.106	CbGbCtD
Lisuride—ADRA1B—vas deferens—prostate cancer	0.0299	0.461	CbGeAlD
Lisuride—CYP3A4—Bicalutamide—prostate cancer	0.0295	0.0811	CbGbCtD
Lisuride—CYP3A4—Estramustine—prostate cancer	0.0274	0.0754	CbGbCtD
Lisuride—CYP3A4—Abiraterone—prostate cancer	0.0244	0.0672	CbGbCtD
Lisuride—CYP3A4—Flutamide—prostate cancer	0.0244	0.0672	CbGbCtD
Lisuride—CYP3A4—Cabazitaxel—prostate cancer	0.0181	0.0497	CbGbCtD
Lisuride—CYP3A4—Estrone—prostate cancer	0.0177	0.0486	CbGbCtD
Lisuride—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0157	0.0433	CbGbCtD
Lisuride—CYP3A4—Conjugated Estrogens—prostate cancer	0.0116	0.0318	CbGbCtD
Lisuride—CYP3A4—Mitoxantrone—prostate cancer	0.0105	0.0289	CbGbCtD
Lisuride—CYP3A4—Estradiol—prostate cancer	0.0101	0.0279	CbGbCtD
Lisuride—CYP3A4—Prednisone—prostate cancer	0.00872	0.024	CbGbCtD
Lisuride—CYP2D6—Doxorubicin—prostate cancer	0.0071	0.0196	CbGbCtD
Lisuride—CYP3A4—Etoposide—prostate cancer	0.00662	0.0182	CbGbCtD
Lisuride—CYP3A4—Docetaxel—prostate cancer	0.00606	0.0167	CbGbCtD
Lisuride—CYP3A4—Doxorubicin—prostate cancer	0.00452	0.0124	CbGbCtD
Lisuride—HTR2A—urine—prostate cancer	0.0027	0.0416	CbGeAlD
Lisuride—ADRA1D—prostate gland—prostate cancer	0.00261	0.0403	CbGeAlD
Lisuride—CYP3A4—urine—prostate cancer	0.0025	0.0386	CbGeAlD
Lisuride—CYP2D6—urine—prostate cancer	0.00246	0.0379	CbGeAlD
Lisuride—DRD4—testis—prostate cancer	0.00218	0.0336	CbGeAlD
Lisuride—ADRA1D—epithelium—prostate cancer	0.00192	0.0296	CbGeAlD
Lisuride—ADRB1—prostate gland—prostate cancer	0.0019	0.0292	CbGeAlD
Lisuride—ADRA1B—renal system—prostate cancer	0.00182	0.0281	CbGeAlD
Lisuride—ADRA1D—urethra—prostate cancer	0.00175	0.027	CbGeAlD
Lisuride—ADRA2C—prostate gland—prostate cancer	0.00143	0.022	CbGeAlD
Lisuride—ADRA2C—seminal vesicle—prostate cancer	0.00121	0.0186	CbGeAlD
Lisuride—ADRA2A—prostate gland—prostate cancer	0.00114	0.0176	CbGeAlD
Lisuride—HTR1A—renal system—prostate cancer	0.00111	0.0171	CbGeAlD
Lisuride—ADRA2C—renal system—prostate cancer	0.000975	0.015	CbGeAlD
Lisuride—ADRA2A—seminal vesicle—prostate cancer	0.000965	0.0149	CbGeAlD
Lisuride—ADRA2C—urethra—prostate cancer	0.000958	0.0148	CbGeAlD
Lisuride—Cabergoline—ADRB2—prostate cancer	0.000834	0.286	CrCbGaD
Lisuride—ADRA2A—urethra—prostate cancer	0.000764	0.0118	CbGeAlD
Lisuride—HTR2A—epithelium—prostate cancer	0.000713	0.011	CbGeAlD
Lisuride—HTR2A—renal system—prostate cancer	0.000661	0.0102	CbGeAlD
Lisuride—DRD2—testis—prostate cancer	0.000648	0.00998	CbGeAlD
Lisuride—ADRA2C—testis—prostate cancer	0.00063	0.00971	CbGeAlD
Lisuride—CYP3A4—renal system—prostate cancer	0.000612	0.00943	CbGeAlD
Lisuride—CYP2D6—renal system—prostate cancer	0.000602	0.00928	CbGeAlD
Lisuride—HTR2B—lymph node—prostate cancer	0.00058	0.00894	CbGeAlD
Lisuride—Ergonovine—CYP3A4—prostate cancer	0.000522	0.179	CrCbGaD
Lisuride—ADRA2A—testis—prostate cancer	0.000503	0.00775	CbGeAlD
Lisuride—ADRA2C—lymph node—prostate cancer	0.000457	0.00704	CbGeAlD
Lisuride—Cabergoline—CYP3A4—prostate cancer	0.000457	0.157	CrCbGaD
Lisuride—Methylergometrine—CYP3A4—prostate cancer	0.000457	0.157	CrCbGaD
Lisuride—HTR2A—testis—prostate cancer	0.000427	0.00659	CbGeAlD
Lisuride—CYP2D6—testis—prostate cancer	0.000389	0.006	CbGeAlD
Lisuride—ADRA2A—lymph node—prostate cancer	0.000364	0.00561	CbGeAlD
Lisuride—Pergolide—CYP3A4—prostate cancer	0.000353	0.121	CrCbGaD
Lisuride—Dehydration—Capecitabine—prostate cancer	0.00034	0.00139	CcSEcCtD
Lisuride—Orthostatic hypotension—Capecitabine—prostate cancer	0.000334	0.00137	CcSEcCtD
Lisuride—Vomiting—Bicalutamide—prostate cancer	0.000333	0.00136	CcSEcCtD
Lisuride—Insomnia—Goserelin—prostate cancer	0.000329	0.00134	CcSEcCtD
Lisuride—Headache—Bicalutamide—prostate cancer	0.000328	0.00134	CcSEcCtD
Lisuride—Insomnia—Conjugated Estrogens—prostate cancer	0.000326	0.00133	CcSEcCtD
Lisuride—Dyspnoea—Goserelin—prostate cancer	0.000324	0.00132	CcSEcCtD
Lisuride—Somnolence—Goserelin—prostate cancer	0.000324	0.00132	CcSEcCtD
Lisuride—Dyspnoea—Conjugated Estrogens—prostate cancer	0.000321	0.00131	CcSEcCtD
Lisuride—Somnolence—Conjugated Estrogens—prostate cancer	0.00032	0.00131	CcSEcCtD
Lisuride—Vertigo—Estradiol—prostate cancer	0.000318	0.0013	CcSEcCtD
Lisuride—Asthenia—Ethinyl Estradiol—prostate cancer	0.000317	0.0013	CcSEcCtD
Lisuride—Syncope—Estradiol—prostate cancer	0.000317	0.00129	CcSEcCtD
Lisuride—Decreased appetite—Goserelin—prostate cancer	0.000316	0.00129	CcSEcCtD
Lisuride—Fatigue—Goserelin—prostate cancer	0.000314	0.00128	CcSEcCtD
Lisuride—Decreased appetite—Conjugated Estrogens—prostate cancer	0.000313	0.00128	CcSEcCtD
Lisuride—Palpitations—Estradiol—prostate cancer	0.000312	0.00128	CcSEcCtD
Lisuride—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000311	0.00127	CcSEcCtD
Lisuride—Constipation—Goserelin—prostate cancer	0.000311	0.00127	CcSEcCtD
Lisuride—Fatigue—Conjugated Estrogens—prostate cancer	0.000311	0.00127	CcSEcCtD
Lisuride—Cough—Estradiol—prostate cancer	0.000308	0.00126	CcSEcCtD
Lisuride—Constipation—Conjugated Estrogens—prostate cancer	0.000308	0.00126	CcSEcCtD
Lisuride—Abdominal discomfort—Capecitabine—prostate cancer	0.000303	0.00124	CcSEcCtD
Lisuride—Anxiety—Estradiol—prostate cancer	0.0003	0.00122	CcSEcCtD
Lisuride—Feeling abnormal—Goserelin—prostate cancer	0.0003	0.00122	CcSEcCtD
Lisuride—Weight increased—Docetaxel—prostate cancer	0.000297	0.00121	CcSEcCtD
Lisuride—Weight decreased—Docetaxel—prostate cancer	0.000296	0.00121	CcSEcCtD
Lisuride—Dry mouth—Estradiol—prostate cancer	0.000294	0.0012	CcSEcCtD
Lisuride—Ergotamine—CYP3A4—prostate cancer	0.000294	0.101	CrCbGaD
Lisuride—Dizziness—Ethinyl Estradiol—prostate cancer	0.000292	0.00119	CcSEcCtD
Lisuride—Cardiac disorder—Etoposide—prostate cancer	0.000292	0.00119	CcSEcCtD
Lisuride—Confusional state—Estradiol—prostate cancer	0.000291	0.00119	CcSEcCtD
Lisuride—Weight increased—Capecitabine—prostate cancer	0.000288	0.00118	CcSEcCtD
Lisuride—Cough—Mitoxantrone—prostate cancer	0.000287	0.00117	CcSEcCtD
Lisuride—Infection—Estradiol—prostate cancer	0.000287	0.00117	CcSEcCtD
Lisuride—Weight decreased—Capecitabine—prostate cancer	0.000286	0.00117	CcSEcCtD
Lisuride—Angiopathy—Etoposide—prostate cancer	0.000286	0.00117	CcSEcCtD
Lisuride—Immune system disorder—Etoposide—prostate cancer	0.000284	0.00116	CcSEcCtD
Lisuride—Mediastinal disorder—Etoposide—prostate cancer	0.000284	0.00116	CcSEcCtD
Lisuride—Nervous system disorder—Estradiol—prostate cancer	0.000283	0.00116	CcSEcCtD
Lisuride—Tachycardia—Estradiol—prostate cancer	0.000282	0.00115	CcSEcCtD
Lisuride—Vomiting—Ethinyl Estradiol—prostate cancer	0.000281	0.00115	CcSEcCtD
Lisuride—Anxiety—Mitoxantrone—prostate cancer	0.000279	0.00114	CcSEcCtD
Lisuride—Hyperhidrosis—Estradiol—prostate cancer	0.000279	0.00114	CcSEcCtD
Lisuride—Headache—Ethinyl Estradiol—prostate cancer	0.000277	0.00113	CcSEcCtD
Lisuride—Confusional state—Mitoxantrone—prostate cancer	0.000271	0.00111	CcSEcCtD
Lisuride—Infection—Mitoxantrone—prostate cancer	0.000267	0.00109	CcSEcCtD
Lisuride—Tachycardia—Mitoxantrone—prostate cancer	0.000262	0.00107	CcSEcCtD
Lisuride—Asthenia—Goserelin—prostate cancer	0.000261	0.00107	CcSEcCtD
Lisuride—Insomnia—Estradiol—prostate cancer	0.000261	0.00107	CcSEcCtD
Lisuride—Hyperhidrosis—Mitoxantrone—prostate cancer	0.00026	0.00106	CcSEcCtD
Lisuride—Asthenia—Conjugated Estrogens—prostate cancer	0.000259	0.00106	CcSEcCtD
Lisuride—Oedema peripheral—Docetaxel—prostate cancer	0.000258	0.00105	CcSEcCtD
Lisuride—Dyspnoea—Estradiol—prostate cancer	0.000257	0.00105	CcSEcCtD
Lisuride—Somnolence—Estradiol—prostate cancer	0.000256	0.00105	CcSEcCtD
Lisuride—Weight increased—Prednisone—prostate cancer	0.000256	0.00105	CcSEcCtD
Lisuride—Anorexia—Mitoxantrone—prostate cancer	0.000256	0.00105	CcSEcCtD
Lisuride—Weight decreased—Prednisone—prostate cancer	0.000255	0.00104	CcSEcCtD
Lisuride—Decreased appetite—Estradiol—prostate cancer	0.000251	0.00102	CcSEcCtD
Lisuride—Oedema peripheral—Capecitabine—prostate cancer	0.000249	0.00102	CcSEcCtD
Lisuride—Gastrointestinal disorder—Estradiol—prostate cancer	0.000249	0.00102	CcSEcCtD
Lisuride—Fatigue—Estradiol—prostate cancer	0.000249	0.00102	CcSEcCtD
Lisuride—Constipation—Estradiol—prostate cancer	0.000247	0.00101	CcSEcCtD
Lisuride—Vertigo—Etoposide—prostate cancer	0.000246	0.00101	CcSEcCtD
Lisuride—Cardiac disorder—Docetaxel—prostate cancer	0.000243	0.000991	CcSEcCtD
Lisuride—Dizziness—Goserelin—prostate cancer	0.000241	0.000983	CcSEcCtD
Lisuride—Dyspnoea—Mitoxantrone—prostate cancer	0.00024	0.000979	CcSEcCtD
Lisuride—Cough—Etoposide—prostate cancer	0.000239	0.000976	CcSEcCtD
Lisuride—Somnolence—Mitoxantrone—prostate cancer	0.000239	0.000976	CcSEcCtD
Lisuride—Dizziness—Conjugated Estrogens—prostate cancer	0.000238	0.000973	CcSEcCtD
Lisuride—Feeling abnormal—Estradiol—prostate cancer	0.000238	0.000971	CcSEcCtD
Lisuride—Angiopathy—Docetaxel—prostate cancer	0.000237	0.000969	CcSEcCtD
Lisuride—Dehydration—Epirubicin—prostate cancer	0.000237	0.000968	CcSEcCtD
Lisuride—Immune system disorder—Docetaxel—prostate cancer	0.000236	0.000965	CcSEcCtD
Lisuride—Mediastinal disorder—Docetaxel—prostate cancer	0.000236	0.000963	CcSEcCtD
Lisuride—Cardiac disorder—Capecitabine—prostate cancer	0.000235	0.00096	CcSEcCtD
Lisuride—Decreased appetite—Mitoxantrone—prostate cancer	0.000234	0.000954	CcSEcCtD
Lisuride—Orthostatic hypotension—Epirubicin—prostate cancer	0.000233	0.000951	CcSEcCtD
Lisuride—Fatigue—Mitoxantrone—prostate cancer	0.000232	0.000946	CcSEcCtD
Lisuride—Vomiting—Goserelin—prostate cancer	0.000231	0.000945	CcSEcCtD
Lisuride—Constipation—Mitoxantrone—prostate cancer	0.00023	0.000939	CcSEcCtD
Lisuride—Angiopathy—Capecitabine—prostate cancer	0.00023	0.000938	CcSEcCtD
Lisuride—Vomiting—Conjugated Estrogens—prostate cancer	0.000229	0.000936	CcSEcCtD
Lisuride—Mental disorder—Docetaxel—prostate cancer	0.000229	0.000936	CcSEcCtD
Lisuride—Immune system disorder—Capecitabine—prostate cancer	0.000229	0.000934	CcSEcCtD
Lisuride—Mediastinal disorder—Capecitabine—prostate cancer	0.000228	0.000932	CcSEcCtD
Lisuride—Headache—Goserelin—prostate cancer	0.000228	0.000931	CcSEcCtD
Lisuride—Malnutrition—Docetaxel—prostate cancer	0.000228	0.00093	CcSEcCtD
Lisuride—Headache—Conjugated Estrogens—prostate cancer	0.000226	0.000922	CcSEcCtD
Lisuride—Confusional state—Etoposide—prostate cancer	0.000225	0.000921	CcSEcCtD
Lisuride—Hallucination—Prednisone—prostate cancer	0.000224	0.000916	CcSEcCtD
Lisuride—Infection—Etoposide—prostate cancer	0.000222	0.000907	CcSEcCtD
Lisuride—Mental disorder—Capecitabine—prostate cancer	0.000222	0.000906	CcSEcCtD
Lisuride—Feeling abnormal—Mitoxantrone—prostate cancer	0.000222	0.000905	CcSEcCtD
Lisuride—Malnutrition—Capecitabine—prostate cancer	0.00022	0.0009	CcSEcCtD
Lisuride—Dehydration—Doxorubicin—prostate cancer	0.000219	0.000896	CcSEcCtD
Lisuride—Tachycardia—Etoposide—prostate cancer	0.000218	0.000891	CcSEcCtD
Lisuride—Hyperhidrosis—Etoposide—prostate cancer	0.000216	0.000883	CcSEcCtD
Lisuride—Orthostatic hypotension—Doxorubicin—prostate cancer	0.000216	0.00088	CcSEcCtD
Lisuride—Anorexia—Etoposide—prostate cancer	0.000213	0.00087	CcSEcCtD
Lisuride—Asthenia—Estradiol—prostate cancer	0.000207	0.000845	CcSEcCtD
Lisuride—Angiopathy—Prednisone—prostate cancer	0.000205	0.000836	CcSEcCtD
Lisuride—Syncope—Docetaxel—prostate cancer	0.000204	0.000834	CcSEcCtD
Lisuride—Immune system disorder—Prednisone—prostate cancer	0.000204	0.000832	CcSEcCtD
Lisuride—Palpitations—Docetaxel—prostate cancer	0.000201	0.000822	CcSEcCtD
Lisuride—Weight increased—Epirubicin—prostate cancer	0.000201	0.000819	CcSEcCtD
Lisuride—Weight decreased—Epirubicin—prostate cancer	0.000199	0.000814	CcSEcCtD
Lisuride—Dyspnoea—Etoposide—prostate cancer	0.000199	0.000814	CcSEcCtD
Lisuride—Somnolence—Etoposide—prostate cancer	0.000199	0.000812	CcSEcCtD
Lisuride—Cough—Docetaxel—prostate cancer	0.000199	0.000811	CcSEcCtD
Lisuride—Vertigo—Capecitabine—prostate cancer	0.000198	0.000809	CcSEcCtD
Lisuride—Syncope—Capecitabine—prostate cancer	0.000198	0.000807	CcSEcCtD
Lisuride—Mental disorder—Prednisone—prostate cancer	0.000198	0.000807	CcSEcCtD
Lisuride—Malnutrition—Prednisone—prostate cancer	0.000196	0.000802	CcSEcCtD
Lisuride—Palpitations—Capecitabine—prostate cancer	0.000195	0.000795	CcSEcCtD
Lisuride—Decreased appetite—Etoposide—prostate cancer	0.000194	0.000794	CcSEcCtD
Lisuride—Gastrointestinal disorder—Etoposide—prostate cancer	0.000193	0.000788	CcSEcCtD
Lisuride—Asthenia—Mitoxantrone—prostate cancer	0.000193	0.000788	CcSEcCtD
Lisuride—Fatigue—Etoposide—prostate cancer	0.000193	0.000787	CcSEcCtD
Lisuride—Cough—Capecitabine—prostate cancer	0.000192	0.000786	CcSEcCtD
Lisuride—Constipation—Etoposide—prostate cancer	0.000191	0.000781	CcSEcCtD
Lisuride—Dizziness—Estradiol—prostate cancer	0.000191	0.000779	CcSEcCtD
Lisuride—Dry mouth—Docetaxel—prostate cancer	0.00019	0.000774	CcSEcCtD
Lisuride—Sweating—Epirubicin—prostate cancer	0.000188	0.000769	CcSEcCtD
Lisuride—Confusional state—Docetaxel—prostate cancer	0.000187	0.000765	CcSEcCtD
Lisuride—Anxiety—Capecitabine—prostate cancer	0.000187	0.000764	CcSEcCtD
Lisuride—Weight increased—Doxorubicin—prostate cancer	0.000186	0.000758	CcSEcCtD
Lisuride—Infection—Docetaxel—prostate cancer	0.000185	0.000754	CcSEcCtD
Lisuride—Weight decreased—Doxorubicin—prostate cancer	0.000185	0.000753	CcSEcCtD
Lisuride—Feeling abnormal—Etoposide—prostate cancer	0.000184	0.000752	CcSEcCtD
Lisuride—Dry mouth—Capecitabine—prostate cancer	0.000184	0.00075	CcSEcCtD
Lisuride—Vomiting—Estradiol—prostate cancer	0.000183	0.000749	CcSEcCtD
Lisuride—Nervous system disorder—Docetaxel—prostate cancer	0.000182	0.000744	CcSEcCtD
Lisuride—Confusional state—Capecitabine—prostate cancer	0.000181	0.000741	CcSEcCtD
Lisuride—Tachycardia—Docetaxel—prostate cancer	0.000181	0.000741	CcSEcCtD
Lisuride—Headache—Estradiol—prostate cancer	0.000181	0.000738	CcSEcCtD
Lisuride—Infection—Capecitabine—prostate cancer	0.000179	0.00073	CcSEcCtD
Lisuride—Anorexia—Docetaxel—prostate cancer	0.000177	0.000723	CcSEcCtD
Lisuride—Nervous system disorder—Capecitabine—prostate cancer	0.000176	0.00072	CcSEcCtD
Lisuride—Vertigo—Prednisone—prostate cancer	0.000176	0.00072	CcSEcCtD
Lisuride—Syncope—Prednisone—prostate cancer	0.000176	0.000719	CcSEcCtD
Lisuride—Tachycardia—Capecitabine—prostate cancer	0.000176	0.000717	CcSEcCtD
Lisuride—Sweating—Doxorubicin—prostate cancer	0.000174	0.000712	CcSEcCtD
Lisuride—Hyperhidrosis—Capecitabine—prostate cancer	0.000174	0.00071	CcSEcCtD
Lisuride—Oedema peripheral—Epirubicin—prostate cancer	0.000174	0.00071	CcSEcCtD
Lisuride—Anorexia—Capecitabine—prostate cancer	0.000171	0.0007	CcSEcCtD
Lisuride—Vomiting—Mitoxantrone—prostate cancer	0.000171	0.000698	CcSEcCtD
Lisuride—Headache—Mitoxantrone—prostate cancer	0.000168	0.000688	CcSEcCtD
Lisuride—Insomnia—Docetaxel—prostate cancer	0.000168	0.000686	CcSEcCtD
Lisuride—Anxiety—Prednisone—prostate cancer	0.000167	0.00068	CcSEcCtD
Lisuride—Dyspnoea—Docetaxel—prostate cancer	0.000166	0.000677	CcSEcCtD
Lisuride—Somnolence—Docetaxel—prostate cancer	0.000165	0.000675	CcSEcCtD
Lisuride—Cardiac disorder—Epirubicin—prostate cancer	0.000164	0.000669	CcSEcCtD
Lisuride—Insomnia—Capecitabine—prostate cancer	0.000163	0.000664	CcSEcCtD
Lisuride—Decreased appetite—Docetaxel—prostate cancer	0.000162	0.00066	CcSEcCtD
Lisuride—Oedema peripheral—Doxorubicin—prostate cancer	0.000161	0.000657	CcSEcCtD
Lisuride—Gastrointestinal disorder—Docetaxel—prostate cancer	0.00016	0.000655	CcSEcCtD
Lisuride—Asthenia—Etoposide—prostate cancer	0.00016	0.000655	CcSEcCtD
Lisuride—Dyspnoea—Capecitabine—prostate cancer	0.00016	0.000655	CcSEcCtD
Lisuride—Fatigue—Docetaxel—prostate cancer	0.00016	0.000654	CcSEcCtD
Lisuride—Angiopathy—Epirubicin—prostate cancer	0.00016	0.000654	CcSEcCtD
Lisuride—Immune system disorder—Epirubicin—prostate cancer	0.000159	0.000651	CcSEcCtD
Lisuride—Infection—Prednisone—prostate cancer	0.000159	0.00065	CcSEcCtD
Lisuride—Mediastinal disorder—Epirubicin—prostate cancer	0.000159	0.000649	CcSEcCtD
Lisuride—Constipation—Docetaxel—prostate cancer	0.000159	0.000649	CcSEcCtD
Lisuride—Nervous system disorder—Prednisone—prostate cancer	0.000157	0.000642	CcSEcCtD
Lisuride—Tachycardia—Prednisone—prostate cancer	0.000156	0.000639	CcSEcCtD
Lisuride—Decreased appetite—Capecitabine—prostate cancer	0.000156	0.000639	CcSEcCtD
Lisuride—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000155	0.000634	CcSEcCtD
Lisuride—Fatigue—Capecitabine—prostate cancer	0.000155	0.000633	CcSEcCtD
Lisuride—Hyperhidrosis—Prednisone—prostate cancer	0.000155	0.000633	CcSEcCtD
Lisuride—Mental disorder—Epirubicin—prostate cancer	0.000155	0.000631	CcSEcCtD
Lisuride—Constipation—Capecitabine—prostate cancer	0.000154	0.000628	CcSEcCtD
Lisuride—Malnutrition—Epirubicin—prostate cancer	0.000154	0.000627	CcSEcCtD
Lisuride—Feeling abnormal—Docetaxel—prostate cancer	0.000153	0.000625	CcSEcCtD
Lisuride—Anorexia—Prednisone—prostate cancer	0.000153	0.000624	CcSEcCtD
Lisuride—Cardiac disorder—Doxorubicin—prostate cancer	0.000151	0.000619	CcSEcCtD
Lisuride—Feeling abnormal—Capecitabine—prostate cancer	0.000148	0.000605	CcSEcCtD
Lisuride—Angiopathy—Doxorubicin—prostate cancer	0.000148	0.000605	CcSEcCtD
Lisuride—Dizziness—Etoposide—prostate cancer	0.000148	0.000604	CcSEcCtD
Lisuride—Immune system disorder—Doxorubicin—prostate cancer	0.000147	0.000602	CcSEcCtD
Lisuride—Mediastinal disorder—Doxorubicin—prostate cancer	0.000147	0.000601	CcSEcCtD
Lisuride—Insomnia—Prednisone—prostate cancer	0.000145	0.000592	CcSEcCtD
Lisuride—Mental disorder—Doxorubicin—prostate cancer	0.000143	0.000584	CcSEcCtD
Lisuride—Vomiting—Etoposide—prostate cancer	0.000142	0.000581	CcSEcCtD
Lisuride—Malnutrition—Doxorubicin—prostate cancer	0.000142	0.00058	CcSEcCtD
Lisuride—Headache—Etoposide—prostate cancer	0.00014	0.000572	CcSEcCtD
Lisuride—Decreased appetite—Prednisone—prostate cancer	0.000139	0.000569	CcSEcCtD
Lisuride—Fatigue—Prednisone—prostate cancer	0.000138	0.000564	CcSEcCtD
Lisuride—Vertigo—Epirubicin—prostate cancer	0.000138	0.000563	CcSEcCtD
Lisuride—Syncope—Epirubicin—prostate cancer	0.000138	0.000562	CcSEcCtD
Lisuride—Constipation—Prednisone—prostate cancer	0.000137	0.00056	CcSEcCtD
Lisuride—Palpitations—Epirubicin—prostate cancer	0.000136	0.000554	CcSEcCtD
Lisuride—Cough—Epirubicin—prostate cancer	0.000134	0.000547	CcSEcCtD
Lisuride—Asthenia—Docetaxel—prostate cancer	0.000133	0.000544	CcSEcCtD
Lisuride—Feeling abnormal—Prednisone—prostate cancer	0.000132	0.000539	CcSEcCtD
Lisuride—Anxiety—Epirubicin—prostate cancer	0.00013	0.000532	CcSEcCtD
Lisuride—Asthenia—Capecitabine—prostate cancer	0.000129	0.000527	CcSEcCtD
Lisuride—Dry mouth—Epirubicin—prostate cancer	0.000128	0.000522	CcSEcCtD
Lisuride—Vertigo—Doxorubicin—prostate cancer	0.000128	0.000521	CcSEcCtD
Lisuride—Syncope—Doxorubicin—prostate cancer	0.000127	0.00052	CcSEcCtD
Lisuride—Confusional state—Epirubicin—prostate cancer	0.000126	0.000516	CcSEcCtD
Lisuride—Palpitations—Doxorubicin—prostate cancer	0.000126	0.000513	CcSEcCtD
Lisuride—Infection—Epirubicin—prostate cancer	0.000125	0.000508	CcSEcCtD
Lisuride—Cough—Doxorubicin—prostate cancer	0.000124	0.000506	CcSEcCtD
Lisuride—Nervous system disorder—Epirubicin—prostate cancer	0.000123	0.000502	CcSEcCtD
Lisuride—Dizziness—Docetaxel—prostate cancer	0.000123	0.000502	CcSEcCtD
Lisuride—Tachycardia—Epirubicin—prostate cancer	0.000122	0.0005	CcSEcCtD
Lisuride—Hyperhidrosis—Epirubicin—prostate cancer	0.000121	0.000495	CcSEcCtD
Lisuride—Anxiety—Doxorubicin—prostate cancer	0.000121	0.000492	CcSEcCtD
Lisuride—Anorexia—Epirubicin—prostate cancer	0.000119	0.000488	CcSEcCtD
Lisuride—Dizziness—Capecitabine—prostate cancer	0.000119	0.000486	CcSEcCtD
Lisuride—Dry mouth—Doxorubicin—prostate cancer	0.000118	0.000483	CcSEcCtD
Lisuride—Vomiting—Docetaxel—prostate cancer	0.000118	0.000482	CcSEcCtD
Lisuride—Confusional state—Doxorubicin—prostate cancer	0.000117	0.000478	CcSEcCtD
Lisuride—Headache—Docetaxel—prostate cancer	0.000116	0.000475	CcSEcCtD
Lisuride—Infection—Doxorubicin—prostate cancer	0.000115	0.00047	CcSEcCtD
Lisuride—Asthenia—Prednisone—prostate cancer	0.000115	0.00047	CcSEcCtD
Lisuride—Vomiting—Capecitabine—prostate cancer	0.000114	0.000467	CcSEcCtD
Lisuride—Nervous system disorder—Doxorubicin—prostate cancer	0.000114	0.000464	CcSEcCtD
Lisuride—Insomnia—Epirubicin—prostate cancer	0.000113	0.000463	CcSEcCtD
Lisuride—Tachycardia—Doxorubicin—prostate cancer	0.000113	0.000462	CcSEcCtD
Lisuride—Headache—Capecitabine—prostate cancer	0.000113	0.00046	CcSEcCtD
Lisuride—Hyperhidrosis—Doxorubicin—prostate cancer	0.000112	0.000458	CcSEcCtD
Lisuride—Dyspnoea—Epirubicin—prostate cancer	0.000112	0.000456	CcSEcCtD
Lisuride—Somnolence—Epirubicin—prostate cancer	0.000111	0.000455	CcSEcCtD
Lisuride—Anorexia—Doxorubicin—prostate cancer	0.000111	0.000451	CcSEcCtD
Lisuride—Decreased appetite—Epirubicin—prostate cancer	0.000109	0.000445	CcSEcCtD
Lisuride—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000108	0.000442	CcSEcCtD
Lisuride—Fatigue—Epirubicin—prostate cancer	0.000108	0.000441	CcSEcCtD
Lisuride—Constipation—Epirubicin—prostate cancer	0.000107	0.000438	CcSEcCtD
Lisuride—Dizziness—Prednisone—prostate cancer	0.000106	0.000433	CcSEcCtD
Lisuride—Insomnia—Doxorubicin—prostate cancer	0.000105	0.000428	CcSEcCtD
Lisuride—Dyspnoea—Doxorubicin—prostate cancer	0.000103	0.000422	CcSEcCtD
Lisuride—Feeling abnormal—Epirubicin—prostate cancer	0.000103	0.000422	CcSEcCtD
Lisuride—Somnolence—Doxorubicin—prostate cancer	0.000103	0.000421	CcSEcCtD
Lisuride—Vomiting—Prednisone—prostate cancer	0.000102	0.000416	CcSEcCtD
Lisuride—Decreased appetite—Doxorubicin—prostate cancer	0.000101	0.000412	CcSEcCtD
Lisuride—Headache—Prednisone—prostate cancer	0.0001	0.00041	CcSEcCtD
Lisuride—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.0001	0.000409	CcSEcCtD
Lisuride—Fatigue—Doxorubicin—prostate cancer	0.0001	0.000408	CcSEcCtD
Lisuride—Constipation—Doxorubicin—prostate cancer	9.92e-05	0.000405	CcSEcCtD
Lisuride—Feeling abnormal—Doxorubicin—prostate cancer	9.56e-05	0.00039	CcSEcCtD
Lisuride—Asthenia—Epirubicin—prostate cancer	8.99e-05	0.000367	CcSEcCtD
Lisuride—Asthenia—Doxorubicin—prostate cancer	8.32e-05	0.00034	CcSEcCtD
Lisuride—Dizziness—Epirubicin—prostate cancer	8.29e-05	0.000338	CcSEcCtD
Lisuride—Vomiting—Epirubicin—prostate cancer	7.97e-05	0.000325	CcSEcCtD
Lisuride—Headache—Epirubicin—prostate cancer	7.85e-05	0.000321	CcSEcCtD
Lisuride—Dizziness—Doxorubicin—prostate cancer	7.67e-05	0.000313	CcSEcCtD
Lisuride—Vomiting—Doxorubicin—prostate cancer	7.37e-05	0.000301	CcSEcCtD
Lisuride—Headache—Doxorubicin—prostate cancer	7.27e-05	0.000297	CcSEcCtD
Lisuride—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	3.41e-06	1.95e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—EP300—prostate cancer	3.41e-06	1.95e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PTEN—prostate cancer	3.4e-06	1.94e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	3.39e-06	1.94e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—KRAS—prostate cancer	3.39e-06	1.94e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—EP300—prostate cancer	3.37e-06	1.93e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GGT1—prostate cancer	3.37e-06	1.93e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CCND1—prostate cancer	3.37e-06	1.93e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NOS3—prostate cancer	3.37e-06	1.93e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	3.34e-06	1.91e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CXCL8—prostate cancer	3.34e-06	1.91e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—AKT1—prostate cancer	3.33e-06	1.91e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MMP9—prostate cancer	3.32e-06	1.9e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—NCOA1—prostate cancer	3.32e-06	1.9e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—AKT1—prostate cancer	3.32e-06	1.9e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	3.31e-06	1.89e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—SRC—prostate cancer	3.31e-06	1.89e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PTEN—prostate cancer	3.31e-06	1.89e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MYC—prostate cancer	3.3e-06	1.89e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TGFB1—prostate cancer	3.29e-06	1.88e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CXCL8—prostate cancer	3.28e-06	1.88e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—SRC—prostate cancer	3.28e-06	1.88e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MMP9—prostate cancer	3.27e-06	1.87e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.27e-06	1.87e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—JAK2—prostate cancer	3.27e-06	1.87e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	3.26e-06	1.86e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—EP300—prostate cancer	3.26e-06	1.86e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MYC—prostate cancer	3.26e-06	1.86e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CDKN1B—prostate cancer	3.26e-06	1.86e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MYC—prostate cancer	3.26e-06	1.86e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTEN—prostate cancer	3.25e-06	1.86e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	3.25e-06	1.86e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TGFB1—prostate cancer	3.25e-06	1.86e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—EP300—prostate cancer	3.24e-06	1.85e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—KRAS—prostate cancer	3.23e-06	1.85e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	3.23e-06	1.85e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—EGFR—prostate cancer	3.23e-06	1.85e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—VEGFA—prostate cancer	3.23e-06	1.84e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	3.22e-06	1.84e-05	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—AKT1—prostate cancer	3.22e-06	1.84e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTEN—prostate cancer	3.21e-06	1.84e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	3.21e-06	1.83e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	3.2e-06	1.83e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	3.2e-06	1.83e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—STAT3—prostate cancer	3.19e-06	1.83e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MDM2—prostate cancer	3.19e-06	1.83e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CASP3—prostate cancer	3.19e-06	1.83e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL2—prostate cancer	3.19e-06	1.82e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—EGFR—prostate cancer	3.19e-06	1.82e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—EGFR—prostate cancer	3.19e-06	1.82e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	3.17e-06	1.82e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—IL6—prostate cancer	3.17e-06	1.81e-05	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	3.17e-06	1.81e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—SRC—prostate cancer	3.17e-06	1.81e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—STAT3—prostate cancer	3.16e-06	1.81e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	3.16e-06	1.81e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CG—prostate cancer	3.16e-06	1.81e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—RXRA—prostate cancer	3.16e-06	1.81e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—EP300—prostate cancer	3.15e-06	1.8e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—SRC—prostate cancer	3.15e-06	1.8e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	3.15e-06	1.8e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CASP3—prostate cancer	3.14e-06	1.8e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL2—prostate cancer	3.14e-06	1.79e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TP53—prostate cancer	3.13e-06	1.79e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—IL6—prostate cancer	3.12e-06	1.78e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—PIK3CA—prostate cancer	3.11e-06	1.78e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CCND1—prostate cancer	3.11e-06	1.78e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	3.11e-06	1.78e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—EP300—prostate cancer	3.1e-06	1.77e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—VEGFA—prostate cancer	3.09e-06	1.76e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CTNNB1—prostate cancer	3.08e-06	1.76e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—VEGFA—prostate cancer	3.07e-06	1.76e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—SRC—prostate cancer	3.07e-06	1.75e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—EP300—prostate cancer	3.06e-06	1.75e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TP53—prostate cancer	3.06e-06	1.75e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCND1—prostate cancer	3.06e-06	1.75e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—STAT3—prostate cancer	3.05e-06	1.75e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—KRAS—prostate cancer	3.05e-06	1.74e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—COMT—prostate cancer	3.04e-06	1.74e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—STAT3—prostate cancer	3.04e-06	1.74e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	3.03e-06	1.73e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTP1—prostate cancer	3.03e-06	1.73e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—SRC—prostate cancer	3.02e-06	1.73e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MMP9—prostate cancer	3.02e-06	1.73e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TP53—prostate cancer	3.01e-06	1.72e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—KRAS—prostate cancer	3.01e-06	1.72e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—KRAS—prostate cancer	3.01e-06	1.72e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CDKN1A—prostate cancer	3.01e-06	1.72e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTEN—prostate cancer	3e-06	1.72e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—INS—prostate cancer	2.99e-06	1.71e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	2.99e-06	1.71e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	2.99e-06	1.71e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ITPR1—prostate cancer	2.98e-06	1.7e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	2.97e-06	1.7e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MMP9—prostate cancer	2.97e-06	1.7e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MYC—prostate cancer	2.97e-06	1.7e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TGFB1—prostate cancer	2.96e-06	1.69e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	2.96e-06	1.69e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—STAT3—prostate cancer	2.96e-06	1.69e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTEN—prostate cancer	2.95e-06	1.69e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MYC—prostate cancer	2.94e-06	1.68e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	2.94e-06	1.68e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	2.93e-06	1.68e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—CREBBP—prostate cancer	2.93e-06	1.68e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—AKT1—prostate cancer	2.93e-06	1.67e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	2.92e-06	1.67e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—STAT3—prostate cancer	2.91e-06	1.66e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—EGFR—prostate cancer	2.9e-06	1.66e-05	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	2.88e-06	1.65e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—AKT1—prostate cancer	2.88e-06	1.65e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—EGFR—prostate cancer	2.88e-06	1.65e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TP53—prostate cancer	2.87e-06	1.64e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—IL6—prostate cancer	2.86e-06	1.64e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—EP300—prostate cancer	2.86e-06	1.64e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CASP3—prostate cancer	2.86e-06	1.63e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL2—prostate cancer	2.85e-06	1.63e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—IL6—prostate cancer	2.84e-06	1.62e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MYC—prostate cancer	2.84e-06	1.62e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TGFB1—prostate cancer	2.83e-06	1.62e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MYC—prostate cancer	2.82e-06	1.62e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TGFB1—prostate cancer	2.82e-06	1.61e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—TYMS—prostate cancer	2.81e-06	1.61e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—EP300—prostate cancer	2.81e-06	1.61e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PIK3CA—prostate cancer	2.8e-06	1.6e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—IL6—prostate cancer	2.8e-06	1.6e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PIK3CA—prostate cancer	2.79e-06	1.6e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTM1—prostate cancer	2.78e-06	1.59e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCND1—prostate cancer	2.78e-06	1.59e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—SRC—prostate cancer	2.78e-06	1.59e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.78e-06	1.59e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—EGFR—prostate cancer	2.78e-06	1.59e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	2.76e-06	1.58e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PIK3CA—prostate cancer	2.76e-06	1.58e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—EGFR—prostate cancer	2.76e-06	1.58e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—IL6—prostate cancer	2.76e-06	1.58e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	2.75e-06	1.58e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MYC—prostate cancer	2.75e-06	1.57e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—KRAS—prostate cancer	2.74e-06	1.57e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	2.74e-06	1.57e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—SRC—prostate cancer	2.74e-06	1.57e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—LPL—prostate cancer	2.73e-06	1.56e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—KRAS—prostate cancer	2.72e-06	1.55e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TP53—prostate cancer	2.71e-06	1.55e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—VEGFA—prostate cancer	2.71e-06	1.55e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MYC—prostate cancer	2.7e-06	1.55e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MMP9—prostate cancer	2.7e-06	1.54e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	2.7e-06	1.54e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	2.69e-06	1.54e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—EGFR—prostate cancer	2.69e-06	1.54e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTEN—prostate cancer	2.68e-06	1.54e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—STAT3—prostate cancer	2.68e-06	1.53e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TP53—prostate cancer	2.67e-06	1.53e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TP53—prostate cancer	2.67e-06	1.53e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—VEGFA—prostate cancer	2.67e-06	1.52e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—EGFR—prostate cancer	2.64e-06	1.51e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—AKT1—prostate cancer	2.64e-06	1.51e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—STAT3—prostate cancer	2.64e-06	1.51e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.64e-06	1.51e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—IL6—prostate cancer	2.63e-06	1.51e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—NOS3—prostate cancer	2.62e-06	1.5e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—KRAS—prostate cancer	2.62e-06	1.5e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	2.62e-06	1.5e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ERCC2—prostate cancer	2.62e-06	1.5e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—KRAS—prostate cancer	2.61e-06	1.49e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—AKT1—prostate cancer	2.58e-06	1.48e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—EP300—prostate cancer	2.56e-06	1.46e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—AKT1—prostate cancer	2.54e-06	1.45e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—KRAS—prostate cancer	2.54e-06	1.45e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	2.52e-06	1.44e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—KRAS—prostate cancer	2.5e-06	1.43e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	2.5e-06	1.43e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MYC—prostate cancer	2.49e-06	1.43e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—SRC—prostate cancer	2.49e-06	1.42e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TGFB1—prostate cancer	2.49e-06	1.42e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—IL6—prostate cancer	2.48e-06	1.42e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—MTHFR—prostate cancer	2.46e-06	1.41e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MYC—prostate cancer	2.45e-06	1.4e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—IL6—prostate cancer	2.45e-06	1.4e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—IL6—prostate cancer	2.45e-06	1.4e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TGFB1—prostate cancer	2.45e-06	1.4e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—EGFR—prostate cancer	2.44e-06	1.39e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TP53—prostate cancer	2.44e-06	1.39e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—AKT1—prostate cancer	2.43e-06	1.39e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	2.42e-06	1.39e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CB—prostate cancer	2.42e-06	1.38e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TP53—prostate cancer	2.41e-06	1.38e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PPARA—prostate cancer	2.41e-06	1.38e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	2.41e-06	1.38e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—STAT3—prostate cancer	2.4e-06	1.37e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTGS2—prostate cancer	2.4e-06	1.37e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—EGFR—prostate cancer	2.4e-06	1.37e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	2.4e-06	1.37e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	2.33e-06	1.33e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TP53—prostate cancer	2.33e-06	1.33e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TP53—prostate cancer	2.32e-06	1.33e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—KRAS—prostate cancer	2.3e-06	1.32e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	2.29e-06	1.31e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—AKT1—prostate cancer	2.29e-06	1.31e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—AKT1—prostate cancer	2.28e-06	1.3e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CAV1—prostate cancer	2.27e-06	1.3e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—KRAS—prostate cancer	2.27e-06	1.3e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CA—prostate cancer	2.27e-06	1.3e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—AKT1—prostate cancer	2.26e-06	1.29e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—AKT1—prostate cancer	2.26e-06	1.29e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TP53—prostate cancer	2.26e-06	1.29e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MYC—prostate cancer	2.23e-06	1.28e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL6—prostate cancer	2.23e-06	1.28e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	2.23e-06	1.27e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TP53—prostate cancer	2.22e-06	1.27e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL6—prostate cancer	2.21e-06	1.26e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—EGFR—prostate cancer	2.18e-06	1.25e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL6—prostate cancer	2.13e-06	1.22e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL6—prostate cancer	2.12e-06	1.21e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CA—prostate cancer	2.12e-06	1.21e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTEN—prostate cancer	2.09e-06	1.2e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	2.08e-06	1.19e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.07e-06	1.18e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL6—prostate cancer	2.06e-06	1.18e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—KRAS—prostate cancer	2.06e-06	1.18e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—AKT1—prostate cancer	2.06e-06	1.18e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TP53—prostate cancer	2.05e-06	1.17e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—AKT1—prostate cancer	2.04e-06	1.17e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL6—prostate cancer	2.03e-06	1.16e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TP53—prostate cancer	2.01e-06	1.15e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—EP300—prostate cancer	2e-06	1.14e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—AKT1—prostate cancer	1.97e-06	1.13e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—AKT1—prostate cancer	1.96e-06	1.12e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—INS—prostate cancer	1.96e-06	1.12e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CREBBP—prostate cancer	1.92e-06	1.1e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—AKT1—prostate cancer	1.9e-06	1.09e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	1.89e-06	1.08e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—AKT1—prostate cancer	1.87e-06	1.07e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL6—prostate cancer	1.87e-06	1.07e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—AKT1—prostate cancer	1.85e-06	1.06e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL6—prostate cancer	1.84e-06	1.05e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TP53—prostate cancer	1.83e-06	1.05e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.82e-06	1.04e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—AKT1—prostate cancer	1.73e-06	9.89e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—NOS3—prostate cancer	1.71e-06	9.81e-06	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—AKT1—prostate cancer	1.7e-06	9.73e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL6—prostate cancer	1.68e-06	9.59e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.58e-06	9.05e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTGS2—prostate cancer	1.57e-06	8.97e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT1—prostate cancer	1.55e-06	8.85e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.48e-06	8.44e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTEN—prostate cancer	1.37e-06	7.82e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—EP300—prostate cancer	1.3e-06	7.46e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AKT1—prostate cancer	1.21e-06	6.9e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CA—prostate cancer	9.65e-07	5.52e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AKT1—prostate cancer	7.88e-07	4.51e-06	CbGpPWpGaD
